Swiss drugmaker Roche plans to complete its US$4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday, December 17, after US authorities ruled the deal would not hurt competition in hemophilia A treatment.
The Federal Trade Commission (FTC) and Britain’s Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales.
Roche is buying US-based Spark to expand in gene therapy and boost its hemophilia A portfolio, where the Basel-based company’s existing drug Hemlibra will surpass US$1 billion sales in 2019.
Regulators had feared Roche might sabotage Spark’s hemophilia program to benefit Hemlibra, but came to another conclusion.
“The evidence developed during staff’s investigation did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its hemophilia A gene therapy,” the FTC stated after its 5-0 approval vote.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Nvidia and Microsoft Sued for Allegedly Undercutting AI Technology Patent Prices
Sep 5, 2024 by
CPI
White & Case Strengthens Antitrust and M&A Practices with New Partner Additions
Sep 5, 2024 by
CPI
Federal Judge Dismisses Antitrust Lawyers’ Fee Demand Over JetBlue-Spirit Deal
Sep 5, 2024 by
CPI
Boston Landlords Named as US Sues RealPage Over Alleged Rent-Inflating Practices
Sep 5, 2024 by
CPI
Judge to Weigh Landmark NCAA Settlement Proposal in Antitrust Lawsuit
Sep 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
CPI
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
CPI
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
CPI
The Cost of Making COFECE Disappear
Sep 3, 2024 by
CPI